Amprius Technologies, Inc. filings document operating results, material events, governance matters and capital-structure disclosures for a public battery technology company. Its 8-K reports include quarterly and annual financial-result releases, material agreement updates, auditor changes, lease-related matters, and equity offering activity.
Amprius disclosure records also cover proxy and shareholder voting matters, emerging growth company status, common stock, redeemable warrants, and board and executive compensation topics. These filings provide the formal record for the company's silicon-anode battery business, security structure, financing activity, risk disclosures and corporate governance practices.
Amprius Technologies insider plans sizable stock sale. A Form 144 filing indicates that Stefan Constantin Ionel intends to sell 717,307 shares of AMPX common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate market value of $8,012,319.19. The filing notes that 130,483,838 shares of the company’s common stock are outstanding.
The shares to be sold were acquired on 01/21/2026 through the cash exercise of stock options for the same 717,307-share amount. The form also reports prior sales over the past three months, including 125,000 and 73,255 shares sold on 12/11/2025 for gross proceeds of $1,313,575.00 and $769,807.49, and 25,024 shares sold on 11/21/2025 for $252,274.45. The filing includes a representation that the seller is not aware of undisclosed material adverse information about the issuer’s operations.
Amprius Technologies director Kang Sun reported option exercises and share sales under a pre-arranged trading plan. On January 16, 2026, he exercised stock options for 850,338 shares at $2.5 per share and 100,210 shares at $1.78 per share, then sold 950,548 shares of common stock at an average price of $11.0659 per share. On January 20, 2026, he exercised options for 43,185 shares at $1.78 per share and sold the same number of shares at an average price of $11.0287 per share.
Following these transactions, Sun directly beneficially owned 1,403,651 shares of Amprius common stock, including 1,285,576 restricted stock units, and indirectly held 274,275 shares through the Kang & Cecillia Sun Family Revocable Trust, where he and his spouse are co-trustees. The filing states that the exercises and sales were effected pursuant to a Rule 10b5-1 trading plan adopted on August 18, 2025.
A shareholder filed a Form 144 to sell 1,018,875 common shares on the NYSE, showing an aggregate market value of $10,341,581.25. The shares are to be sold through Morgan Stanley Smith Barney LLC, with an approximate sale date of 01/16/2026, and the filing notes that 130,483,838 shares of the issuer’s stock are outstanding.
The securities to be sold were acquired on 01/16/2026 via the exercise of stock options from the issuer, paid in cash. Over the past three months, the same account reported additional common stock sales, including 1,000,000 shares sold on 11/17/2025 for $10,595,300.00 and 506,267 shares sold on 01/12/2026 for $5,111,474.14, some under a Rule 10b5-1 trading plan.
Amprius Technologies director Sun Kang reported multiple option exercises and a share sale. On January 12, 2026, he exercised three stock option grants for 180,802 shares at $0.62, 208,264 shares at $2.44, and 117,201 shares at $2.50 per share, receiving the same number of common shares in each case. He then sold 506,267 shares of common stock at an average price of $10.0964 under a Rule 10b5-1 trading plan adopted on August 18, 2025.
After these transactions, Sun directly beneficially owned 1,403,651 shares of common stock, which includes 1,285,576 restricted stock units, and held 850,338 stock options directly. In addition, 274,275 shares are held indirectly by the KANG & CECILLIA SUN FAMILY REVOCABLE TRUST, for which he and his spouse serve as co-trustees.
A holder of AMPX common stock has filed a notice of proposed sale under Rule 144 after exercising stock options. The filer plans to sell 506,267 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an indicated aggregate market value of 4,799,411.16. The approximate sale date is 01/12/2026, and the shares were acquired the same day by cash exercise of stock options from the issuer.
The notice also reports prior sales of the issuer’s common stock during the past three months by the same seller. These include 68,655 shares sold on 11/21/2025 for gross proceeds of 692,131.65, and 1,000,000 shares sold on 11/17/2025 under a Rule 10b5-1 trading plan for gross proceeds of 10,595,300.00. The filing represents that the seller is not aware of undisclosed material adverse information about the issuer.
Amprius Technologies, Inc. reported that it has completed all sales under its at-the-market equity offering program. The program, established under a sales agreement with B. Riley Securities, Cantor Fitzgerald and H.C. Wainwright, authorized offers of common stock up to an aggregate offering price of $100.0 million.
The company issued a total of 25.5 million shares of common stock through this program, generating aggregate net proceeds of approximately $97.5 million. During the three months ended December 31, 2025, Amprius sold additional shares for aggregate net proceeds of about $19.6 million at an average price of $11.17 per share, at which point the program was concluded and the sales agreement terminated in accordance with its terms.
Amprius Technologies, Inc. disclosed that a director and officer serving as President received an equity award in the form of restricted stock units. On December 19, 2025, the reporting person acquired 200,000 shares of common stock at a price of $0, as noted in a footnote describing these shares as restricted stock units granted on that date, with a vesting commencement date of January 1, 2026.
Each restricted stock unit represents the right to receive one share of Amprius common stock. One quarter of the award will vest on February 20, 2027, and the remaining units will vest in equal quarterly installments over the following three years on May 20, August 20, November 20 and February 20, until fully vested on February 20, 2030, subject to continued service. After this transaction, the reporting person beneficially owns 610,000 shares, including 600,000 restricted stock units subject to their respective vesting schedules and conditions.
Amprius Technologies announced a leadership transition. Chief Executive Officer Dr. Kang Sun told the board he will step down from his officer role effective December 31, 2025, and become Executive Advisor on January 1, 2026, while remaining on the board. The company states his decision is not due to any disagreement over operations, policies, or practices.
Amprius entered into a new employment agreement with Dr. Sun, giving him a $633,000 annual salary without bonus eligibility and providing six months of salary continuation and partial accelerated equity vesting if he is terminated without cause, resigns for good reason, or upon death or disability, with full stock option vesting if this occurs in connection with a change in control. Current President Tom Stepien has been appointed Chief Executive Officer effective January 1, 2026, with a $633,000 base salary, a target annual cash bonus equal to 100% of salary, and a grant of 200,000 restricted stock units that vest over four years.
Amprius Technologies’ Chief Technology Officer reported option exercises and share sales in December. On 12/11/2025, he exercised stock options for 125,000 shares of common stock at an exercise price of $0.05 per share, increasing his direct holdings.
On the same date, he sold 198,255 shares of common stock at an average price of $10.5086 per share, with individual trade prices ranging from $10.14 to $11.49. After these transactions, he directly held 748,696 shares, which includes 585,697 restricted stock units that vest over time, and 310,962 stock options remained outstanding. The exercises and sales were carried out under a Rule 10b5-1 trading plan adopted on September 11, 2025.
A shareholder has filed to sell common stock under Rule 144. The notice covers a proposed sale of 198,255 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $2,188,735.20 and 130,483,838 shares of the class outstanding.
The shares to be sold come from recent and prior equity awards, including 125,000 shares acquired on December 11, 2025 through a stock option exercise for cash, 43,464 shares from restricted stock units granted on May 20, 2024, and 29,791 shares from stock options previously exercised on December 14, 2022. In the past three months, the seller, Stefan Constantin Ionel, already sold 25,024 common shares on November 21, 2025 for gross proceeds of $252,274.45.